TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03521414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS) monitoring
Description: When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS) monitoring
Description: When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bispectral index (BIS) monitoring
Description: When the patients were taken to the operation table, they were monitored with the BIS. we used sevoflurane drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: we used sevoflurane drug at inoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: we used sevoflurane drug at inoperative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: we used sevoflurane drug at inoperative
Study: NCT04549519

Intervention type: OTHER
Intervention: No intervention
Description: No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control

Intervention type: OTHER
Intervention: No intervention
Description: No intervention / Compare the difference in batting mechanics and bat-swing velocity in baseball players with good and poor lumbopelvic control
Study: NCT00978835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored telephone-based case management
Description: Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse Education
Description: Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
Study: NCT00905684

Intervention type: DRUG
Intervention: EE30/DRSP (Yasmin, BAY86-5131)
Description: Patients under regular daily life treatment receiving Yasmin according to local drug information

Intervention type: DRUG
Intervention: Any other OC
Description: Patients under regular daily life treatment receiving any other OC according to local drug information
Study: NCT04130503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP
Description: Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAP
Description: Positive airway pressure (PAP) treatment of obstructive sleep apnea (OSA).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLE
Description: All patients (randomized and non-randomized) will receive a healthy lifestyle education (HLE) intervention focused on secondary stroke prevention.
Study: NCT01009554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Potassium Oxylate Mouthwash
Description: Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride Dentifrice
Description: Brush in usual manner, twice daily, with a sodium fluoride dentifrice
Study: NCT00800943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (Campath-1H)
Description: Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
Study: NCT01172405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen plus caffeine
Description: One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: One or two tablets of ibuprofen 400 mg when presenting headache.
Study: NCT01813851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise training in addition to nutritional support
Study: NCT01973946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Symptom Alert and Coaching
Description: Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
Study: NCT01975818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY 85-3934)
Description: Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY 85-3934)
Description: Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY 85-3934)
Description: Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY 85-3934)
Description: Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa/beta
Study: NCT00238667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet (Aspirin, Dipyridamole, clopidogrel)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
Study: NCT04566627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yo Sé Lo Que Quiero programl
Description: Yo Sé Lo Que Quiero program is the cultural adaptation of the Unplugged program. This is a preventive intervention to reduce tobacco, alcohol, and marihuana use among adolescents. It consists of 12 sessions, delivered by a trained facilitator on a weekly basis.
Study: NCT02209337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SRS
Study: NCT04561804

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy (LSG) and laparoscopic single anastomosis gastric bypass (LSAGB)
Description: The participants will receive nutritional recommendations for a low carbohydrate, low glycemic load, and isocaloric diet. The diet will be composed of carbohydrates (CHO;35%), fats (40-50%), and proteins (20-25%), and will be tailored to individual preferences and calorie requirements. The number of CHO, protein and fat servings will be determined based on the recommended total energy requirements for age, calculated on the basis of dietary reference intake (DRI). Participants will not be instructed to restrict calories, but to reduce carbohydrate based on their glycemic load.~The subjects will be instructed about appropriate food choices, and each subject was provided a diet information booklet containing food list, sample menus and recipes
Study: NCT01351623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
Study: NCT02054325

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polidocanol with Glucose
Description: An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
Study: NCT01649570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
Study: NCT01326728

Intervention type: BIOLOGICAL
Intervention: Allogeneic stem cell transplant
Description: Donors will undergo cell collection and recipients will receive cells (allotransplant).
Study: NCT01159912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate inhalation powder, 250 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: Fluticasone furoate inhalation powder, 100 µg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation powder
Study: NCT03805009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Gait Training (RAGT)
Description: The Robotic Group (RG) performs a Robot-Assisted Gait Training (RAGT) using an end-effector robotic device (G-EO system-Reha Technology-Olten, Switzerland).
Study: NCT04288895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: 5 - 20 mg/day flexible-dose vortioxetine, tablets, orally
Study: NCT05568602

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone suppression test
Description: 1 mg Dexamethasone overnight suppression test for screening of hypercortisolism

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone suppression test
Description: 1 mg Dexamethasone overnight suppression test for screening of hypercortisolism
Study: NCT02301936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed dose combination (FDC) tablet administered orally once daily
Study: NCT02540538

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVaxPro
Description: 3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBAI20
Description: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBAI20
Description: 2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
Study: NCT04563000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Ascorbic acid 1,5 g intravenously every 12-hours for 4 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9 % solution of sodium chloride 100 ml intravenously every 12-hours for 4 consecutive days
Study: NCT02506478

Intervention type: OTHER
Intervention: Beverage procurement
Description: All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
Study: NCT02926469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality during labor
Study: NCT00408603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voreloxin Injection
Description: All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
Study: NCT04139057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EBV-specific TCR-T cell with anti-PD1 auto-secreted element
Description: Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
Study: NCT04087954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stigma reduction program
Description: Participants in the intervention group received treatment as usual, supported with stigma reduction program booklets each fortnight for 26 weeks. The stigma reduction program includes three modules; psychoeducation, cognitive behavioural therapy and social skills training. The program aims to enhance patient understanding of Schizophrenia and foster communication skills which supposed to increase self-confidence and strengthen communication networking with society.~Psychoeducation module purposes at introducing about the concepts of schizophrenia, providing patient with essential information about schizophrenia, including nature of disease, sign/symptoms, treatment strategies, side effects of medication. Social Skills Training (SST) module purposes at fostering communication skills among patient diagnosed with schizophrenia. This assists the participants to be re-integrated in the society and build a harmonious atmosphere in the community.
Study: NCT05261971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac 400 MG
Description: Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac 400 MG
Description: Patients were asked to drink a tablet containing 400 mg of etodolac every 24 hours with a glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside
Description: Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiocolchicoside
Description: Patients were asked to drink a tablet containing 4 mg of thiocolchicoside every 24 hours with a glass of water.
Study: NCT01923116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine
Description: Vaccination with SLP-HPV-01® with or without interferon-a injections.
Study: NCT04181944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Treatment Group
Description: be specific
Study: NCT01102803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy (CBT)
Description: The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Individual Cognitive Behavioral Therapy (CBT)
Description: The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: D-Cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study: NCT04254744

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane inhalation for anesthesia

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane inhalation for anesthesia
Study: NCT03920150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Patient will be treated with 3 doses of alcoholic solution for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D oily capsules
Description: Patient will be treated with 3 capsules for 3 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D oily capsules
Description: Patient will be treated with weekly capsules for an individually calculated number of weeks.
Study: NCT02336763

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo external beam radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03859713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Evidence-based physical therapy provided in 8 individual sessions including patient education, exercise instruction and manual therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Evidence-based cognitive behavioral therapy provided in 8 individual sessions focused on key components of CBT; 1) identifying and monitoring maladaptive cognitions, 2) developing coping strategies (e.g., distraction, relaxation, etc.), 3) setting and working towards behavioral goals, especially focused on physical activity, and 4) focusing on self-management skills and home instruction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness is provided in 8 individual sessions. Focus of sessions is cognitive reappraisal, positive savoring and mindfulness practices.
Study: NCT04403750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined laser-surgical technology of RRD treatment
Description: 1. Nd-YAG laser excision of the vitreoretinal traction zone~2. Pneumatic retinopexy (10% C3F8)~3. barrier laser photocoagulation around retinal break after retinal attachment (2-3 days after pneumatic retinopexy)
Study: NCT01667107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calogen®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calogen®
Study: NCT03061461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rESWT
Description: All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith \& Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).~In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rESWT
Description: All patients will receive standard care as follows:~1. Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.~2. The clean wounds will be assessed using the TIME concept.~3. Treatment with sham rESWT.~4. Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).~In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT.
Study: NCT03536390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)
Description: Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06012383

Intervention type: DRUG
Intervention: Bortezomib
Description: Alvocade® was given with a dose of 1.3 mg/m2.
Study: NCT00947778

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 sessions of evaluation tests
Description: 3 sessions of evaluation tests, each session during 15 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 sessions of evaluation tests
Description: 3 sessions of evaluation tests, each session during 15 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 training session
Description: 20 sessions of 30 minutes by week during 24 semaines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 training session
Description: 20 sessions of 30 minutes by week during 24 semaines